| Recruitment status | Open public recruiting |
| Unique ID issued by UMIN | UMIN000034517 |
| Receipt No. | R000036865 |
| Scientific Title | Intra-articular platelet-rich plasma injections for the patients with osteoarthritis of the knee in the Japanese population: A Prospective, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial |
| Date of disclosure of the study information | 2018/11/01 |
| Last modified on | 2019/10/22 (Ver. 5) |
| Basic information | ||
| Public title | Intra-articular platelet-rich plasma injections for the patients with osteoarthritis of the knee in the Japanese population: A Prospective, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial | |
| Acronym | Platelet-rich plasma injections for the patients with osteoarthritis of the knee in the Japanese population | |
| Scientific Title | Intra-articular platelet-rich plasma injections for the patients with osteoarthritis of the knee in the Japanese population: A Prospective, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial | |
| Scientific Title:Acronym | Platelet-rich plasma injections for the patients with osteoarthritis of the knee in the Japanese population | |
| Region |
|
|
| Condition | ||
| Condition | Osteoarthritis of the knee | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To compare the effectiveness of intra-articular platelet-rich plasma injections with intra-articular saline injection as a placebo for the patients with osteoarthritis of the knee |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Phase II,III |
| Assessment | |
| Primary outcomes | The improvement rate of WOMAC (Western Ontario and McMaster Universities Osteoarthritis) score in comparison between 24 weeks after the start of treatment and before treatment |
| Key secondary outcomes | 1. Visual Analogue Scale for pain after 24 weeks from the start of treatment (at the time of the first injection)
2. The improvement rate of MRI Osteoarthritis Knee Score (MOAKS) |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | Institution is considered as a block. |
| Blocking | |
| Concealment | Central registration |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Intra-articlar injections: Platelet-rich plasma derived from autologous peripheral blood | |
| Interventions/Control_2 | Intra-articlar injections: Saline | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1. With a history of chronic (for at least 3 months) knee joint pain more than 35-mm on 0- to 100-mm visual analogue scale
2. Radiographically documented grades 1-3 osteoarthritis of the knee, grade according to the Kellgren-Lawrence radiographic classification scale 3. With hydrarthrosis or bone marrow lesion or synovitis 4. Requiring infiltration in monolateral knee 5. Possibility for observation during follow-up period |
|||
| Key exclusion criteria | 1. BMI less than 18.5
2. BMI more than 25 3. Suffering from polyarticular disease 4. Valgus knee and varus knee more than 10 degree in X-ray 5. Previous knee arthroscopy within 6 months 6. HA or steroid intra-articular infiltration within last 1 month 7. Past history of infectious disease 8. Skin disease in knee 9. Compromised host 10. Systemic autoimmune disease 11. Anemia with hemoglobin under 9.0 g/dl 12. Blood disorders 13. Treatment with anticoagulant drugs (Aspirin, Warfarin) 14. Having undergone treatment with steroids during 3 months before inclusion in this study 15. Treatment with NSAIDs during 2 weeks before its inclusion in this study 16. Patients who had malignancy during 5 years before inclusion in this study 17. Patients who cannot have a consent with document 18. Patients whom the doctor has determined that it is not suitable for this clinical study |
|||
| Target sample size | 30 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | University of Tsukuba | ||||||
| Division name | Department of Orthopaedic Surgery, Faculty of Medicine | ||||||
| Zip code | 3058575 | ||||||
| Address | 1-1-1 Tennodai, Tsukuba, Ibaraki | ||||||
| TEL | 029-853-3219 | ||||||
| masashiy@md.tsukuba.ac.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | University of Tsukuba | ||||||
| Division name | Div. of Regenerative Med. for Musculoskeletal System, Dep. of Orthop. Surgery, Faculty of Medicine | ||||||
| Zip code | 3058575 | ||||||
| Address | 1-1-1 Tennodai, Tsukuba, Ibaraki | ||||||
| TEL | 029-853-3219 | ||||||
| Homepage URL | |||||||
| yoshioka@md.tsukuba.ac.jp | |||||||
| Sponsor | |
| Institute | University of Tsukuba Hospital |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Department of Orthopaedics Surgery, Faculty of Medicine |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | The Japanese Association for the Promotion of State-of-the-Art in Medicine |
| Address | 13-8 Takamine-cho, Showa-ku Nagoya-shi, Aichi 466-1811, Japan |
| Tel | 052-745-6881 |
| tokutei-nintei@japsam.or.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Open public recruiting | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000036865 |